Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review
Top Cited Papers
- 1 July 2006
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (7) , 845-851
- https://doi.org/10.1136/ard.2006.051391
Abstract
To evaluate the two generations of anti-cyclic citrullinated protein (CCP) antibodies as a diagnostic marker of rheumatoid arthritis (RA) and as a predictor of future development of RA in healthy subjects and in patients with early undifferentiated arthritis. A systematic analysis of the literature published between 1999 and February 2006 was conducted. Data were collected on the sensitivity and specificity of the two generations of anti-CCP antibodies for diagnosing RA and predicting future development of the disease. Among 107 studies initially identified, 68 had interpretable data and were analysed. Diagnostic properties were assessed in 58 studies: mean (SD) sensitivity was 53 (10)% (range 41-68) and 68 (15)% (range 39-94) for anti-CCP1 and anti-CCP2, respectively; mean (SD) specificity was 96 (3)% (range 90-99) and 95 (5)% (range 81-100) for anti-CCP1 and anti-CCP2, respectively. Predictive properties were assessed in 14 studies; odds ratio (95% confidence interval) of anti-CCP1 and anti-CCP2 for the future development of RA were 20 (14 to 31) and 25 (18 to 35), respectively, among patients with early undifferentiated arthritis and 64.5 (8.5 to 489) and 28 (8 to 95), respectively, among healthy subjects. Sensitivity of the second generation of anti-CCP is close to that of rheumatoid factor, with a higher specificity, for distinguishing RA from other rheumatic diseases. Moreover, anti-CCP antibodies appear to be highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis.Keywords
This publication has 80 references indexed in Scilit:
- A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Clinical Utility of the Anti‐CCP Assay: Experiences with 700 PatientsAnnals of the New York Academy of Sciences, 2005
- Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosisClinical Rheumatology, 2005
- Anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2005
- Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patientsClinica Chimica Acta; International Journal of Clinical Chemistry, 2005
- Diagnostic Performances of Anti-Cyclic Citrullinated Peptides Antibody and Antifilaggrin Antibody in Korean Patients with Rheumatoid ArthritisJournal of Korean Medical Science, 2005
- Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvementAnnals of the Rheumatic Diseases, 2004
- Second generation anti‐cyclic citrullinated peptide (anti‐CCP2) antibodies can replace other anti‐filaggrin antibodies and improve rheumatoid arthritis diagnosisScandinavian Journal of Rheumatology, 2004
- Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseasesAnnals of the Rheumatic Diseases, 2004
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988